Hereditary Cancer Syndromes

Hereditary cancer syndromes are inherited conditions in which a germline alteration — usually in a tumour-suppressor or DNA-repair gene — substantially raises a person's lifetime risk of one or more cancers, often at younger ages and in characteristic patterns across a family. Although they account for a minority of all cancers, they were central to understanding how cancer genes work and they define groups for whom risk assessment and tailored surveillance are considered.

Definition

A hereditary cancer syndrome is a disorder caused by a germline (inherited) pathogenic variant that confers a markedly increased, often autosomal-dominant, predisposition to specific cancers, typically with earlier onset and clustering of cancers within families.

Scope

The topic covers the genetic basis of inherited cancer predisposition, the two-hit model that explains tumour-suppressor syndromes, the major recognised syndromes and their associated cancers, and the features that raise suspicion of a hereditary cause. It is reference knowledge about the syndromes and their biology, not a protocol for genetic testing or risk-reducing intervention in an individual.

Core questions

• How do inherited germline variants raise cancer risk, and why are most such syndromes due to tumour-suppressor or DNA-repair genes?
• What clinical and family-history features suggest a hereditary rather than sporadic cause of cancer?
• Which are the major hereditary cancer syndromes and what cancers are they associated with?
• How does identifying a syndrome change risk assessment for the individual and their relatives?

Key concepts

• Germline versus somatic mutation
• Tumour-suppressor genes
• Two-hit hypothesis
• Autosomal-dominant inheritance with variable penetrance
• Hereditary breast and ovarian cancer (BRCA1/BRCA2)
• Lynch syndrome and mismatch-repair deficiency
• Familial adenomatous polyposis
• Cancer family history red flags

Key theories

Knudson two-hit hypothesis

In tumour-suppressor syndromes an individual inherits one defective allele in every cell, so a single additional somatic 'hit' is enough to inactivate the gene and initiate cancer, explaining the earlier and often bilateral or multifocal disease seen in inherited cases.

Mechanisms

Most hereditary cancer syndromes follow from a germline pathogenic variant in a tumour-suppressor or DNA-repair gene. Knudson's analysis of retinoblastoma established the two-hit model: an inherited first hit present in all cells means only one further somatic event is needed to lose gene function, which accounts for the earlier onset and the multifocal or bilateral tumours typical of inherited disease. In hereditary breast and ovarian cancer, germline BRCA1 or BRCA2 variants impair homologous-recombination DNA repair and substantially raise breast and ovarian cancer risk; in Lynch syndrome, defective DNA mismatch repair drives microsatellite instability and predisposes especially to colorectal and endometrial cancer. The shared theme is that an inherited defect in genome maintenance lowers the threshold for malignant transformation.

Clinical relevance

Recognising features that suggest a hereditary syndrome — young age at diagnosis, multiple primary cancers, characteristic cancer combinations, and a strong family history — frames when genetic evaluation may be relevant and explains why relatives may share risk. This entry describes the syndromes and their biology as reference knowledge and does not provide individualized recommendations on genetic testing, surveillance schedules, or risk-reducing procedures, which are determined by current guidelines and specialist assessment.

Epidemiology

Hereditary syndromes account for a minority of cancers overall — on the order of a small percentage for most common cancers — but they confer high relative risks within affected families. Inherited BRCA1 and BRCA2 variants markedly elevate lifetime breast and ovarian cancer risk, and Lynch syndrome is among the more common inherited predispositions to colorectal and endometrial cancer, with risks that depend on the specific gene and variant.

History

The genetics of inherited cancer was opened up by Knudson's 1971 statistical study of retinoblastoma, which inferred the two-hit model later confirmed at the molecular level. Family-based studies, notably Mary-Claire King's linkage of early-onset breast cancer to a locus on chromosome 17, led to the cloning of BRCA1 in 1994, while Henry Lynch's long study of cancer-prone families defined the syndrome that bears his name and was tied to mismatch-repair deficiency. Together these established the modern framework of hereditary cancer predisposition.

Key figures

• Alfred Knudson
• Mary-Claire King
• Henry Lynch
• Albert de la Chapelle

Seminal works

• knudson-1971
• miki-1994
• lynch-2003

Frequently asked questions

Does inheriting a cancer-predisposition variant mean a person will definitely develop cancer?

No. These variants raise risk, often substantially, but penetrance is incomplete and variable; the specific gene, variant, and other factors influence whether and when cancer develops, so an inherited variant denotes elevated susceptibility rather than certainty.

What features suggest a cancer might be hereditary?

Diagnosis at an unusually young age, multiple primary cancers in one person, characteristic combinations of cancers, and several affected close relatives across generations are recognised clues that prompt consideration of a hereditary syndrome.